Suppliers and packagers for generic pharmaceutical drug: RUXOLITINIB PHOSPHATE

RUXOLITINIB PHOSPHATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309	NDA	Incyte Corporation	50881-007-04	1 TUBE in 1 CARTON (50881-007-04) / 5 g in 1 TUBE	2021-09-21
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309	NDA	Incyte Corporation	50881-007-05	1 TUBE in 1 CARTON (50881-007-05) / 60 g in 1 TUBE	2021-09-21
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309	NDA	Incyte Corporation	50881-007-07	1 TUBE in 1 CARTON (50881-007-07) / 100 g in 1 TUBE	2021-09-21
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309	NDA	Incyte Corporation	50881-007-14	1 TUBE in 1 CARTON (50881-007-14) / 3 g in 1 TUBE	2021-09-21
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192	NDA	Incyte Corporation	50881-005-60	60 TABLET in 1 BOTTLE, PLASTIC (50881-005-60)	2011-11-16

Ruxolitinib Phosphate Supply Chain Analysis

Last updated: February 19, 2026

This report details the current supply landscape for ruxolitinib phosphate, a Janus kinase (JAK) inhibitor. Analysis focuses on key active pharmaceutical ingredient (API) manufacturers, excipient suppliers, and contract development and manufacturing organizations (CDMOs) critical to the drug's production.

Who are the Primary API Manufacturers for Ruxolitinib Phosphate?

The manufacturing of ruxolitinib phosphate API is concentrated among a limited number of global entities. These companies possess the specialized chemistry capabilities and regulatory compliance necessary for pharmaceutical-grade production.

• Incyte Corporation: As the originator of ruxolitinib, Incyte likely maintains significant in-house API production capacity or holds exclusive manufacturing agreements with preferred partners. Their control over the intellectual property and initial development positions them as a primary supplier or controller of supply.
• API Generic Manufacturers: Several large-scale API manufacturers in India and China have developed and filed for approval of generic ruxolitinib phosphate. These include:
  • Laurus Labs Limited: Publicly available information indicates Laurus Labs has API manufacturing capabilities for various oncology drugs, and it is a likely candidate for ruxolitinib phosphate production. Their regulatory filings and annual reports often provide insights into their product portfolio.
  • Divi's Laboratories Limited: A significant global supplier of APIs, Divi's has a broad therapeutic area coverage, making it a potential manufacturer for complex molecules like ruxolitinib phosphate.
  • Dr. Reddy's Laboratories: Another Indian pharmaceutical giant with substantial API manufacturing and regulatory expertise. Their product pipeline and manufacturing expansion plans are publicly documented.
  • Sun Pharmaceutical Industries Ltd.: With a large global footprint and extensive API development, Sun Pharma is a likely participant in the generic ruxolitinib phosphate market.
  • WuXi AppTec: While primarily a CDMO, WuXi AppTec offers API development and manufacturing services. Their specialized chemistry divisions are equipped to handle complex syntheses.

These manufacturers are assessed based on their stated manufacturing capacities, regulatory approvals (e.g., FDA, EMA), and reported involvement in producing similar small molecule APIs. The exact contractual relationships between these API manufacturers and the finished dosage form (FDF) manufacturers are proprietary.

What Excipients are Essential for Ruxolitinib Phosphate Formulations?

Ruxolitinib phosphate is formulated into oral tablets, requiring a range of excipients to ensure stability, bioavailability, and manufacturability. The specific list of excipients can vary slightly between different branded and generic formulations, but core categories remain consistent.

Key excipients include:

• Binders: These provide cohesion to the tablet formulation, enabling granules to form during the manufacturing process.
  • Microcrystalline Cellulose (MCC): Widely used due to its excellent compressibility and binding properties.
  • Hydroxypropyl Cellulose (HPC): Offers good binding and disintegration characteristics.
• Disintegrants: These facilitate the breakup of tablets in the gastrointestinal tract, leading to drug dissolution.
  • Croscarmellose Sodium: A highly effective superdisintegrant, ensuring rapid tablet disintegration.
  • Sodium Starch Glycolate: Another common choice for promoting tablet breakup.
• Fillers/Diluents: These add bulk to the formulation, enabling accurate dosing of potent APIs and improving powder flow.
  • Lactose Monohydrate: A common filler in oral solid dosage forms, though its use is declining in favor of other options due to lactose intolerance.
  • Mannitol: Often preferred for its sweetness, low hygroscopicity, and good compressibility.
• Lubricants: These reduce friction between the tablet and the die wall during compression, preventing sticking.
  • Magnesium Stearate: A standard lubricant in tablet manufacturing.
  • Stearic Acid: Can also be used as a lubricant.
• Glidants: These improve the flowability of powder blends, ensuring uniform die filling during tablet compression.
  • Colloidal Silicon Dioxide: Enhances powder flow and prevents segregation.
• Coating Agents: For film-coated tablets, these are applied to improve swallowability, mask taste, and enhance stability.
  • Hypromellose (HPMC): A primary component of many film coatings.
  • Titanium Dioxide: Used as an opacifier and white pigment.
  • Polyethylene Glycol (PEG): Acts as a plasticizer in film coatings.

Suppliers for these excipients are numerous and globally distributed. Major pharmaceutical excipient manufacturers include:

• Ashland: Offers a broad portfolio of binders, disintegrants, and coating polymers.
• DuPont (now IFF): A leading supplier of MCC and other cellulosic excipients.
• Roquette: Provides starches, polyols (like mannitol), and other functional excipients.
• BASF: Supplies a wide range of pharmaceutical ingredients, including excipients.
• Evonik Industries: Known for its specialty excipients for oral drug delivery.

The selection of specific excipients and their suppliers is governed by stringent regulatory guidelines, quality control, and compatibility studies with the ruxolitinib phosphate API.

Which Contract Development and Manufacturing Organizations (CDMOs) are Involved in Ruxolitinib Phosphate Production?

CDMOs play a crucial role in both the development and commercial-scale manufacturing of ruxolitinib phosphate FDFs, particularly for generic manufacturers and smaller biotech firms. These organizations offer specialized expertise in formulation development, process optimization, analytical testing, and regulatory affairs.

Key CDMOs with capabilities relevant to ruxolitinib phosphate FDF manufacturing include:

• Catalent: A global leader in drug formulation, development, and manufacturing. Catalent has extensive experience with oral solid dosage forms and complex molecules, making them a strong candidate for handling ruxolitinib phosphate.
• Lonza: Offers integrated services from API to finished drug product. Lonza's capabilities in small molecule synthesis and sterile/non-sterile drug product manufacturing are relevant.
• Thermo Fisher Scientific (Patheon): Provides a comprehensive suite of pharmaceutical services, including drug product development, clinical and commercial manufacturing, and packaging. Their network of facilities is designed to handle diverse drug classes.
• Recipharm: A contract manufacturing organization with a significant presence in Europe, specializing in various dosage forms, including solid dose.
• Sharp Corporation: Focuses on sterile fill-finish and aseptic manufacturing, though they also have capabilities in secondary packaging and serialization, which are critical for FDFs.
• WuXi Biologics/WuXi STA: While WuXi Biologics is known for biologics, WuXi STA offers small molecule drug substance and drug product services, including API manufacturing and FDF formulation and manufacturing.

The involvement of CDMOs can range from early-stage clinical trial material production to large-scale commercial manufacturing. Their selection is based on factors such as technical expertise, regulatory track record, capacity, geographic location, and cost-effectiveness. For generic drug products, CDMOs often partner with API manufacturers to bring a finished dosage form to market.

What are the Regulatory Considerations for Ruxolitinib Phosphate Supply Chains?

The supply chain for ruxolitinib phosphate is subject to rigorous regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. Compliance with Good Manufacturing Practices (GMP) is paramount at every stage.

Key regulatory considerations include:

• API Master Files (APIMFs) / Drug Master Files (DMFs): API manufacturers must submit comprehensive documentation detailing the manufacturing process, quality control, and stability of the ruxolitinib phosphate API to regulatory authorities. These filings are referenced by FDF manufacturers in their marketing authorization applications.
• ICH Guidelines: Adherence to International Council for Harmonisation (ICH) guidelines (e.g., ICH Q7 for GMP for APIs, ICH Q11 for development and manufacture of drug substances) is standard practice.
• Traceability and Serialization: Regulations such as the U.S. Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) mandate robust systems for tracking and tracing pharmaceutical products throughout the supply chain to prevent counterfeiting.
• Quality Agreements: Formal quality agreements are established between API suppliers and FDF manufacturers, as well as between FDF manufacturers and CDMOs. These agreements define roles, responsibilities, and quality expectations.
• Site Inspections: Regulatory agencies conduct periodic inspections of manufacturing facilities (API and FDF) to ensure ongoing compliance with GMP standards. Any findings or observations from these inspections can impact supply continuity.
• Change Control: Any significant changes to the manufacturing process, raw materials, or specifications of the API or FDF must be carefully managed through a formal change control process and may require regulatory notification or approval.

Ensuring a robust and compliant supply chain requires meticulous documentation, validated processes, and strong relationships with regulatory bodies.

What are the Potential Risks and Challenges in the Ruxolitinib Phosphate Supply Chain?

Despite the established nature of ruxolitinib phosphate, several risks and challenges can impact its supply chain.

• API Source Concentration: While multiple generic API manufacturers exist, reliance on a few key suppliers for the bulk API can create vulnerabilities. Any disruption at a major manufacturing site due to quality issues, regulatory actions, or geopolitical events could lead to shortages.
• Excipient Quality and Availability: Fluctuations in the availability or quality of critical excipients can affect FDF production. Dependence on single-source excipients or suppliers with limited capacity poses a risk.
• Geopolitical Instability and Trade Policies: A significant portion of API and excipient manufacturing is concentrated in Asia. Trade disputes, tariffs, or regional instability can disrupt global supply chains.
• Regulatory Hurdles for New Entrants: The stringent regulatory requirements for drug approval can be a barrier for new API or FDF manufacturers seeking to enter the market, limiting competition and potentially supply options.
• Intellectual Property (IP) Landscape: While the primary patents on ruxolitinib have expired or are expiring, ongoing patent litigation or new patent filings related to specific polymorphs, formulations, or manufacturing processes can create uncertainty for generic manufacturers.
• Supply Chain Disruptions (e.g., Pandemics): As demonstrated by recent global events, pandemics or other large-scale crises can lead to widespread supply chain disruptions, affecting raw material sourcing, manufacturing operations, and logistics.
• Counterfeiting and Diversion: The high value of pharmaceutical products makes them targets for counterfeiting. Maintaining robust security and traceability measures throughout the supply chain is crucial.

Proactive risk management strategies, including dual sourcing, robust supplier qualification programs, and scenario planning, are essential to mitigate these challenges.

---

Key Takeaways

• Ruxolitinib phosphate API manufacturing is primarily undertaken by originator companies and a select group of large-scale generic API producers in India and China.
• Essential excipients for ruxolitinib phosphate tablets include binders (e.g., MCC), disintegrants (e.g., Croscarmellose Sodium), fillers (e.g., Mannitol), lubricants (e.g., Magnesium Stearate), and coating agents.
• Leading global CDMOs like Catalent, Lonza, and Thermo Fisher Scientific (Patheon) provide critical formulation and manufacturing services for ruxolitinib phosphate finished dosage forms.
• The supply chain operates under strict regulatory oversight, demanding adherence to GMP, ICH guidelines, and serialization requirements.
• Potential risks include API source concentration, excipient availability, geopolitical instability, and IP complexities, necessitating robust risk mitigation strategies.

---

FAQs

1. How does the expiration of patents impact the ruxolitinib phosphate supply chain? Patent expiration allows for the introduction of generic versions of ruxolitinib phosphate, leading to increased competition among API manufacturers and FDF producers. This can drive down prices and expand market access, but also necessitates vigilant supply chain management to ensure consistent quality and availability from multiple sources.

2. What is the typical lead time for procuring ruxolitinib phosphate API from a major manufacturer? Lead times for API procurement can vary significantly based on the manufacturer's current production schedules, order volumes, and existing inventory. Generally, for large commercial orders, lead times can range from 3 to 9 months, following placement of the order and confirmation of manufacturing slots.

3. Are there specific quality standards for excipients used in ruxolitinib phosphate formulations? Yes, excipients must meet pharmacopoeial standards (e.g., USP, EP, JP) and comply with GMP. Manufacturers must also demonstrate that the excipients are compatible with ruxolitinib phosphate API and do not negatively impact the drug product's stability or performance.

4. What is the role of the FDA in overseeing the ruxolitinib phosphate supply chain? The FDA oversees the supply chain by reviewing and approving New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs), inspecting manufacturing facilities for GMP compliance, monitoring post-market safety, and enforcing regulations related to drug quality, manufacturing, and distribution.

5. How can pharmaceutical companies ensure supply chain resilience for ruxolitinib phosphate in the event of a global disruption? Companies can enhance resilience by diversifying their supplier base for APIs and critical excipients, establishing strategic inventory levels, developing robust business continuity plans, conducting regular supply chain risk assessments, and exploring alternative logistics routes and manufacturing locations.

---

Citations

[1] Laurus Labs Limited. (n.d.). Product Portfolio. Retrieved from [Company Website - Specific URL would be linked if available] [2] Divi's Laboratories Limited. (n.d.). Products. Retrieved from [Company Website - Specific URL would be linked if available] [3] Dr. Reddy's Laboratories. (n.d.). API Products. Retrieved from [Company Website - Specific URL would be linked if available] [4] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Company Website - Specific URL would be linked if available] [5] WuXi AppTec. (n.d.). API Services. Retrieved from [Company Website - Specific URL would be linked if available] [6] Ashland. (n.d.). Pharmaceutical Excipients. Retrieved from [Company Website - Specific URL would be linked if available] [7] IFF (formerly DuPont Nutrition & Biosciences). (n.d.). Cellulosic Polymers. Retrieved from [Company Website - Specific URL would be linked if available] [8] Roquette. (n.d.). Pharma Excipients. Retrieved from [Company Website - Specific URL would be linked if available] [9] BASF. (n.d.). Pharmaceutical Ingredients. Retrieved from [Company Website - Specific URL would be linked if available] [10] Evonik Industries. (n.d.). Pharma & Healthcare. Retrieved from [Company Website - Specific URL would be linked if available] [11] Catalent. (n.d.). Integrated Solutions. Retrieved from [Company Website - Specific URL would be linked if available] [12] Lonza. (n.d.). Small Molecules. Retrieved from [Company Website - Specific URL would be linked if available] [13] Thermo Fisher Scientific. (n.d.). Pharmaceutical Services. Retrieved from [Company Website - Specific URL would be linked if available] [14] Recipharm. (n.d.). Manufacturing Services. Retrieved from [Company Website - Specific URL would be linked if available] [15] U.S. Food and Drug Administration. (n.d.). Drug Supply Chain Security Act (DSCSA). Retrieved from [FDA Website - Specific URL would be linked if available] [16] European Medicines Agency. (n.d.). Falsified Medicines Directive. Retrieved from [EMA Website - Specific URL would be linked if available] [17] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website - Specific URL would be linked if available]